UROGEN PHARMA ($URGN) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.92 per share, missing estimates of -$0.82 by $0.10. The company also reported revenue of $20,250,000, missing estimates of $23,260,080 by $-3,010,080.
You can see Quiver Quantitative's $URGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UROGEN PHARMA Insider Trading Activity
UROGEN PHARMA insiders have traded $URGN stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- JASON DREW SMITH (General Counsel) has made 0 purchases and 3 sales selling 7,379 shares for an estimated $82,202.
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 3 sales selling 4,551 shares for an estimated $50,698.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
UROGEN PHARMA Hedge Fund Activity
We have seen 63 institutional investors add shares of UROGEN PHARMA stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK added 1,749,142 shares (+inf%) to their portfolio in Q4 2024, for an estimated $18,628,362
- MORGAN STANLEY removed 1,414,164 shares (-64.8%) from their portfolio in Q4 2024, for an estimated $15,060,846
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,371,638 shares (+inf%) to their portfolio in Q4 2024, for an estimated $14,607,944
- CORMORANT ASSET MANAGEMENT, LP removed 1,250,000 shares (-80.6%) from their portfolio in Q4 2024, for an estimated $13,312,500
- VESTAL POINT CAPITAL, LP added 1,230,000 shares (+307.5%) to their portfolio in Q4 2024, for an estimated $13,099,500
- POINT72 ASSET MANAGEMENT, L.P. removed 1,189,532 shares (-79.0%) from their portfolio in Q4 2024, for an estimated $12,668,515
- UBS GROUP AG added 876,923 shares (+1915.7%) to their portfolio in Q4 2024, for an estimated $9,339,229
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
UROGEN PHARMA Government Contracts
We have seen $204,528 of award payments to $URGN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- JELMYTO KITS: $102,264
- JELMYTO KIT - ANTINEOPLASTIC ANTIBIOTICS: $102,264
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
